$335 | Single User
$670 | Site License
$1005 | Global License

Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

Published by La Merie: 01 May 2016 | 674 | In Stock

Introduction

Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update


Table of Contents


1.         2015 Sales of Anti-CD20 Antibodies


2.         Originator Anti-CD20 Antibodies

Rituxan / MabThera Approved Indications & Pipeline

Gazyva Approved Indications & Pipeline

Arzerra Approved Indications and R&D Pipeline

Zevalin Approved Indications


3.         Biosuperior Anti-CD20 Antibodies

3rd Generation Anti-CD20 Antibodies

Bispecific Anti-CD20 Antibodies

Anti-CD20 Antibody-Drug Conjugates, Immunotoxins & Immunocytokines


4.         Biosimilar Anti-CD20 Antibodies

Rituxan/MabThera Biosimilar Antibodies:

-           Developments in Regulated Markets

-           Developments in Less Regulated Markets

Arzerra Biosimilar Antibodies


5.         Corporate Anti-CD20 Biosimilar & Biosuperior Antibody Pipelines

Table of Contents
for Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

  • Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

    Table of Contents

    1.         2015 Sales of Anti-CD20 Antibodies

    2.         Originator Anti-CD20 Antibodies

    Rituxan / MabThera Approved Indications & Pipeline

    Gazyva Approved Indications & Pipeline

    Arzerra Approved Indications and R&D Pipeline

    Zevalin Approved Indications

    3.         Biosuperior Anti-CD20 Antibodies

    3rd Generation Anti-CD20 Antibodies

    Bispecific Anti-CD20 Antibodies

    Anti-CD20 Antibody-Drug Conjugates, Immunotoxins & Immunocytokines

    4.         Biosimilar Anti-CD20 Antibodies

    Rituxan/MabThera Biosimilar Antibodies:

    -           Developments in Regulated Markets

    -           Developments in Less Regulated Markets

    Arzerra Biosimilar Antibodies

    5.         Corporate Anti-CD20 Biosimilar & Biosuperior Antibody Pipelines

Additional Details

Publisher

La Merie

Publisher Information

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish reports, offer R&D database access, and provide consulting in pharmacology and biotechnology. Our products and subscription services are commercialized via our associated biotech portal PipelineReview.com.

Reference

674 | LMCA0017

Number of Pages

74

Report Format

PDF

La Merie Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases
Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other DiseasesThis Compet...
01 Jun 2016 by La Merie USD $560 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update Humira, Enbrel a...
01 May 2016 by La Merie USD $560 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update This Competitiv...
01 May 2016 by La Merie USD $335 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 UpdateTable of Contents...
01 May 2016 by La Merie USD $335 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 UpdateThis Competitive...
01 May 2016 by La Merie USD $280 More Info
Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update
Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update This Competitive Intelligence report...
01 Apr 2016 by La Merie USD $350 More Info
Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update
Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update This Competitive Intelligence report...
01 Apr 2016 by La Merie USD $350 More Info
Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family
Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) familyThe Compet...
17 Jan 2016 by La Merie USD $225 More Info
Physician Views: And then there were two – will AbbVie's 3-DA regimen prove a compelling competitor to Gilead's Harvoni?
Scope Later this month, the FDA is expected to approve AbbVie's oral '3-DA' product - comprising Vie...
11 Dec 2014 by FirstWord Pharma USD $695 More Info
Physician Views: A Victoza competitor in waiting? – Can Eli Lilly's dulaglutide make an impact in the GLP-1 agonist market?
Scope Last week, Eli Lilly confirmed that in the head-to-head AWARD-6 study its experimental GLP-1 a...
05 Mar 2014 by FirstWord Pharma USD $695 More Info

This report is published by La Merie

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish reports, offer R&D database access, and provide consulting in pharmacology and biotechnology. Our products and subscription services are commercialized via our associated biotech portal PipelineReview.com.

Download Free Report Summary PDF

Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data